DXB 2.27% 45.0¢ dimerix limited

Ann: FDA IND Approval for Phase 3 Study of DMX-200 in FSGS, page-12

  1. 1,981 Posts.
    lightbulb Created with Sketch. 434
    on a serious note....

    where the hell is our first FSGS patient .....

    6 months delay vs expectations.......this is nuts.....Atleast help us understand where the delay is!!

    I am willing to bet anyone that our interim results won't be before end of 2024 at best at this rate of recruitment.... so essentially 18-24 months delay.... company won't say it but slowly they will keep pushing the interim analysis date in presentation out!!

    and it will eventually become a cash flow issue !!
 
watchlist Created with Sketch. Add DXB (ASX) to my watchlist
(20min delay)
Last
45.0¢
Change
0.010(2.27%)
Mkt cap ! $250.3M
Open High Low Value Volume
45.0¢ 46.5¢ 44.0¢ $1.109M 2.457M

Buyers (Bids)

No. Vol. Price($)
1 4348 45.0¢
 

Sellers (Offers)

Price($) Vol. No.
45.5¢ 57615 9
View Market Depth
Last trade - 14.04pm 09/07/2024 (20 minute delay) ?
DXB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.